<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11710825</article-id><article-id pub-id-type="pmc">2375150</article-id><article-id pub-id-type="pii">6692076</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2076</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>IL-2 in combination with IFN-<bold>&#x003b1;</bold>and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Atzpodien</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kirchner</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Illiger</surname><given-names>H J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Metzner</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ukena</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Schott</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Funke</surname><given-names>P J</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Gramatzki</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>J&#x000fc;rgenson</surname><given-names>S von</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wandert</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Patzelt</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Reitz</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><collab>D. G. C. I. N. (German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group)</collab></contrib></contrib-group><aff id="aff1"><label>1</label>Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, Hannover, 30625</aff><aff id="aff2"><label>2</label>Europ&#x000e4;isches Institut f&#x000fc;r Tumor-Immunologie und Pr&#x000e4;vention, Gotenstr. 152, Bonn, 53175</aff><aff id="aff3"><label>3</label>St&#x000e4;dtisches Krankenhaus Siloah, Roesebeckstr. 15, Hannover, 30449</aff><aff id="aff4"><label>4</label>St&#x000e4;dtische Kliniken Oldenburg, Dr.-Eden-Stra&#x003b2;e 10, Oldenburg, 26133</aff><aff id="aff5"><label>5</label>Universit&#x000e4;tskliniken des Saarlandes, Oskar-Orth Stra&#x003b2;e, Homburg/Saar, 66421</aff><aff id="aff6"><label>6</label>Klinikum Ernst-von-Bergmann, Charlottenstr. 72, Potsdam, 14467</aff><aff id="aff7"><label>7</label>Evangelisches Jung-Stilling-Krankenhaus, Wichernstr. 40, Siegen, 57074</aff><aff id="aff8"><label>8</label>Universit&#x000e4;tsklinik Erlangen, Krankenhausstr. 12, Erlangen, 91054, Germany</aff><pub-date pub-type="ppub"><month>10</month><year>2001</year></pub-date><volume>85</volume><issue>8</issue><fpage>1130</fpage><lpage>1136</lpage><history><date date-type="received"><day>21</day><month>02</month><year>2001</year></date><date date-type="rev-recd"><day>17</day><month>07</month><year>2001</year></date><date date-type="accepted"><day>20</day><month>07</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>We conducted a prospectively randomized clinical trial to compare the efficacy and safety of subcutaneous interferon-&#x003b1;2a, subcutaneous interleukin-2 and intravenous 5-fluorouracil as home therapy against oral tamoxifen in 78 patients with progressive metastatic renal cell carcinoma. Treatment courses consisted of interferon-&#x003b1;2a 5 &#x000d7; 10<sup>6</sup>&#x02008;IU&#x02008;m<sup>&#x02212;2</sup>day 1 weeks 1 + 4; days 1, 3, 5 weeks 2 + 3; 10 &#x000d7; 10<sup>6</sup>&#x02008;IU m<sup>&#x02212;2</sup>days 1, 3, 5 weeks 5&#x02013;8; interleukin-2 10 &#x000d7; 10<sup>6</sup>&#x02008;IU&#x02008;m<sup>&#x02212;2</sup>twice daily days 3&#x02013;5 weeks 1 + 4; 5 &#x000d7; 10<sup>6</sup>&#x02008;IU&#x02008;m<sup>&#x02212;2</sup>days 1, 3, 5 weeks 2 + 3; and 5-fluorouracil 1000&#x02008;mg&#x02008;m<sup>&#x02212;2</sup>day 1 weeks 5&#x02013;8. The tamoxifen group received tamoxifen 80&#x02008;mg twice daily over 8 weeks. Among 41 patients treated with interleukin-2, interferon-&#x003b1;2a and 5-fluorouracil there were 7 complete (17.1&#x00025;) and 9 partial responders (21.9&#x00025;), with an overall objective response rate of 39.1&#x00025; (95&#x00025; CI, 24.2&#x02013;55.5). An additional 15 patients (36.6&#x00025;) were stable throughout therapy. The overall survival was 24 months (range 5&#x02013;76+). In 37 patients receiving tamoxifen no objective remissions occurred. 13 patients (35.1&#x00025;) had stable disease and 24 patients (64.9&#x00025;) showed continued disease progression. The overall survival was 13 months (range 3&#x02013;73+). In summary, this home-based therapy regimen of interferon-&#x003b1;2a, interleukin-2 and 5-fluorouracil demonstrated significant therapeutic efficacy in patients with progressive renal cell carcinoma when compared to hormonal therapy. &#x000a9; 2001 Cancer Research Campaign<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">&#x02002;&#x02002;http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>renal cancer</kwd><kwd>interleukin-2</kwd><kwd>interferon-alpha</kwd><kwd>tamoxifen</kwd></kwd-group></article-meta></front></article>


